A Study Comparing Two Types of Supportive Interventions for Caregivers of Patients With Cancer

Cancer Patients Clinical Trial

Official title:

A Randomized Controlled Trial of Emotion Regulation Therapy for Cancer Caregivers: A Mechanism-Targeted Approach to Addressing Caregiver Distress

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04802720
• Other study ID #: 20-407
• Status: Recruiting
• Phase: N/A
• Start date: February 26, 2021
• Est. completion date: January 8, 2025

Study information

• Verified date: May 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: Allison Applebaum, PhD
• Phone: 646-888-0034
• Email: applebaa[@]mskcc.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare two types of therapy for caregivers of cancer patients: Emotion Regulation Therapy for Cancer Caregivers (ERT-C) and Cognitive Behavioral Therapy (CBT-C). The researchers want to see if ERT-C is better than, the same as, or worse than traditional CBT-C at improving caregiver distress. The researchers will look at how the two types of therapy affect caregivers' anxiety, depression, and quality of life. The researchers will also see how ERT-C and CBT-C affect hormone and stress levels in caregivers' saliva samples.

In addition, this trial will enroll cancer patients in this study to see how their caregivers' participation in ERT-C or CBT may affect the patients' quality of life, stress, and use of healthcare services.

Participants who become bereaved while on study will be given the option to withdraw or remain on study. Assessments for bereaved caregivers will not include the Caregiver Quality of Life Index-Cancer (CQOLC) or the Caregiver Reaction Assessment (CRA).

Description:

CBT-C and ERT-C are each 8-session, individual, caregivers-directed interventions delivered by a trained study therapist listed on the face page and facilitated by a manualized workbook with between-session practice exercises. To accommodate caregivers and reduce compliance issues with attendance of sessions, the 8 sessions are to be completed within 8 to 16 weeks from initiation of the first session. Each session is 60 minutes in length and will be audio and video recorded for MSK participants; sessions will only be audio recorded for MGH participants. Specific modules and intervention components are described below. To accommodate as many caregivers as possible and in response to the restrictions placed on caregivers currently in the context of the COVID-19 pandemic, sessions will be offered via telepsychiatry (using WebEx , Zoom, Teams).

Training case participants will be identified and consented onto the study for training purposes only. Participants who are consented as training cases will not be randomized and will not complete any assessments. Data collected on training cases will be used for training and supervision purposes on this study only. These records will not be shown outside of the study supervisors, therapist in training, and staff.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 480
• Est. completion date: January 8, 2025
• Est. primary completion date: January 8, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Caregivers:

• As per self-report, age 18 years or older.

• As per self-report, are a caregiver to an MSK or MGH patient with any site/stage of cancer who has received any type of treatment (e.g. curative, palliative) in the past 12 months.

• Experience distress as evidenced by a score of 4 or greater on the Distress Thermometer (DT) and answer "Yes" to at least one of the follow-up questions (i.e. reporting that their distress is related to their caregiving experience, or their distress started or is related to caregiving or has gotten worse since the patient was diagnosed or began treatment. (N/A for training case participants)

• English fluent: Self-report by subject identifying English as the preferred language for healthcare, and self-reported degree of fluency as speaking English "Very well."

• As per self-report, residing in New York or New Jersey (for MSK participants), or Massachusetts (for MGH participants), or have the ability to complete sessions while complying with current telehealth regulations.

Patients:

• Age 18 years or older as per EMR.

• Patient of an eligible caregiver per self-report or the EMR.

• English speaking as per the EMR or self report by subject identifying English as the preferred language for healthcare, and self-reported degree of fluency as speaking English "Very well.".

Exclusion Criteria:

Caregivers:

• As per self-report, presence of disorder that compromises comprehension of assessments or informed consent information (e.g., dementia).

• As per the judgement of the consenting professional, clinical, PI, and/or as per the medical record, severe psychopathology or cognitive impairment which is likely to interfere with the participation or completion of the protocol or their ability to provide meaningful information

• As per self-report, currently engaged in regular individual psychotherapeutic support (that the participant is unable or unwilling to put on hold for the course of treatment).

• As per self-report, a lifetime history of bipolar disorder, schizophrenia, or schizoaffective disorder.

• As per self-report, has medical condition or medication use known to confound measures of systemic inflammation (e.g., autoimmune disorder, inflammatory disease; uncontrolled thyroid disease; active infection; myocardial infarction or stroke in the last 6 months; Type I diabetes; acute hepatitis; recent vaccination for viral disease). (N/A for training case participants)

• As per self-report, is a regular smoker, defined as having more than 2 cigarettes per day on most days. (N/A for training case participants)

• As per self-report, providing care for a patient who has a caregiver is currently or formerly enrolled in this study ('formerly enrolled' is N/A for training case participants).

• As per self-report, currently enrolled in another study focused on supportive care for caregivers (MGH participants only).

Patients:

• Presence of disorder that compromises comprehension of assessments or informed consent information (e.g., dementia) as per EMR or clinician judgment.

• As per the judgement of the consenting professional, clinical, PI, and/or as per the medical record, severe psychopathology or cognitive impairment which is likely to interfere with the participation or completion of the protocol or their ability to provide meaningful information

Related Conditions & MeSH terms

• Cancer Patients
• Family Caregivers

Intervention

Other:
• Cognitive Behavioral Therapy for Cancer Caregivers (CBT-C)
The sessions are outlined as follow: psychoeducation, goal-setting, and describing the rationale for CBT (Session 1); coping effectiveness training (Session 2); identifying unhelpful cognitions and dysfunctional beliefs (Session 3); challenging and restructuring unhelpful cognitions (Session 4); behavioral activation within the limitations of the caregiving context (Session 5); problem-solving (Session 6); communication strategies and assertiveness training (Session 7); consolidating gains, maintenance, and relapse prevention (Session 8).
• Emotion Regulation Therapy for Cancer Caregivers (ERT-C)
The sessions are outlined as follow: psychoeducation and motivation/dysregulation cue detection within caregiving contexts (Session 1); attention regulation skills training (Sessions 1-2); training in metacognitive skills (Sessions 3-4); exposure to proactive living in the face of risk and loss while applying skills (Sessions 5-7); consolidating gains, taking larger proactive steps, and relapse prevention (Session 8).

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (5)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	Columbia University, University of Aarhus, University of California, University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	changes in anxiety symptoms	as assessed via the HADS Developed by Zigmond and Snaith in 1983, the HADS produces two scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states. Items of the overall severity of anxiety and depression are rated on a five-point (0-4) severity scales (ranging from 0 = no not at all, to 3 = yes definitely), for a total score ranging from 0-21 for each subscale. A higher score indicates higher distress	up to 6 months
Primary	changes in depressive symptoms	as assessed via the HADS Developed by Zigmond and Snaith in 1983, the HADS produces two scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states. Items of the overall severity of anxiety and depression are rated on a five-point (0-4) severity scales (ranging from 0 = no not at all, to 3 = yes definitely), for a total score ranging from 0-21 for each subscale. A higher score indicates higher distress	up to 6 months

External Links

•   Memorial Sloan Kettering Cancer Center